Evidence map›Paper›PMID 37446328›Full record

ArticleInternational journal of molecular sciences2023

Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS.

Hang-Soo Park, Esra Cetin, Hiba Siblini, Jin Seok, Hiba Alkelani, Samar Alkhrait, Farzana Liakath Ali, Mohammad Mousaei Ghasroldasht, Analea Beckman, Ayman Al-Hendy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hang-Soo ParkDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-9130-8478
Esra CetinDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Hiba SibliniDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Jin SeokDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-5805-3736
Hiba AlkelaniDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Samar AlkhraitDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Farzana Liakath AliDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-5921-8571
Mohammad Mousaei GhasroldashtDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-0279-6730
Analea BeckmanDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Ayman Al-HendyDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-8778-4447
University of Chicago · US

Funding

University of Chicago start-up funds
6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is known as the most common endocrine disorder in women. Previously, we suggested that human mesenchymal stem cells (MSCs) can reverse the PCOS condition by secreting factors. Here, we evaluated the therapeutic capability of MSC-derived extracellular vesicles (EVs), also known as exosomes, in both in vitro and in vivo PCOS models. Exosomes were used to treat androgen-producing H293R cells and injected in a mouse model through intraovarian and intravenous injection into a letrozole (LTZ)-induced PCOS mouse model. We assessed the effects of the exosomes on androgen-producing cells or the PCOS mouse model by analyzing steroidogenic gene expression (quantitative real-time polymerase chain reaction (qRT-PCR)), body weight change, serum hormone levels, and fertility by pup delivery. Our data show the therapeutic effect of MSC-derived EVs for reversing PCOS conditions, including fertility issues. Interestingly, intravenous injection was more effective for serum glucose regulation, and an intraovarian injection was more effective for ovary restoration. Our study suggests that MSC-derived exosomes can be promising biopharmaceutics for treating PCOS conditions as a novel therapeutic option. Despite the fact that we need more validation in human patients, we may evaluate this novel treatment option for PCOS with the following clinical trials.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsPolycystic Ovary SyndromeAndrogensAnimalsFemaleHumansMiceAndrogensexosomeextracellular vesiclesfertilityintraovarian injectionintravenous injectionmesenchymal stem cellpolycystic ovary syndrome

Identifiers

PMID37446328
PMCPMC10342552
OpenAlexW4383551200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.